A new structural class of proteasome inhibitors that prevent NF-κB activation

Biochemical Pharmacology

Volumn 55, Issue 9, 1998, Pages 1391-1397

  Lum, Robert T ^a   Kerwar, Suresh S ^a   Meyer, Stephanie M ^a   Nelson, Marek G ^a   Schow, Steven R ^a   Shiffman, Dov ^a   Wick, Michael M ^a   Joly, Alison ^a  

^a CV THERAPEUTICS INC   (United States)

Author keywords

Inflammation; NF B; Proliferation; Proteasome; Proteolysis

Indexed keywords

5 METHOXY 1 INDANONE 3 ACETYL LEUCYL DEXTRO LEUCYL 1 INDANYLAMIDE; CHYMOTRYPSIN; CVT 600; CVT 657; CVT 659; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PHORBOL ESTER; PROTEASOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATTLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BRAIN; CALPAIN; CATTLE; CELL DIVISION; CELL LINE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; FEMALE; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MULTIENZYME COMPLEXES; NF-KAPPA B; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032499406     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00655-2     Document Type: Article

References (26)

1. Coux O, Tanaka K, Goldberg A. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 65:1996;801-847.
2. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science. 268:1995;533-539.
3. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature. 386:1997;463-471.
4. Dahlmann B, Kopp F, Kuehn L, Niedel B, Pfeifer G, Hegerl R, Baumeister W. The multicatalytic proteinase (prosome) is ubiquitous from eukaryotes to archaebacteria. FEBS Lett. 251:1989;125-131.
5. Seemüller E, Lupas A, Zühl F, Zwickl P, Baumeister W. The proteasome from Thermoplasma acidophilum is neither a cysteine nor a serine protease. FEBS Lett. 359:1995;173-178.
6. Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry. 29:1990;10289-10297.
7. Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry. 31:1992;9421-9428.
8. Tsubuki S, Hiroshi K, Saito Y, Miyashita N, Inomata M, Kawashima S. Purification and characterization of a Z-leu-leu-leu-MCA degrading protease expected to regulate neurite formation A novel catalytic activity in proteasome . Biochem Biophys Res Commun. 196:1993;1195-1201.
9. Rock KI, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 78:1994;761-771.
10. Iqbal M, Chatterjee S, Kauer JC, Das M, Messina P, Freed B, Biazzo W, Siman R. Potent inhibitors of proteasome. J Med Chem. 38:1995;2276-2277.
11. Iqbal M, Chatterjee S, Kauer JC, Mallamo JP, Messina PA, Reiboldt A, Siman R. Potent α-ketocarbonyl and boronic ester derived inhibitors of proteasome. Bioorg Med Chem Lett. 6:1996;287-290.
12. Spaltenstein A, Leban JJ, Huang JJ, Reinhardt KR, Viveros OH, Sigafoos J and Crouch R, Design and synthesis of novel protease inhibitors. Tripeptide α′, β′-epoxyketones as nanomolar inactivators of the proteasome. Tetrahedron Lett 37: 1434-1346, 1996.
13. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 268:1995;726-731.
14. Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, Nakagawa A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot (Tokyo). 44:1991;117-118.
15. Fenteany G, Standaert RF, Reichard GA, Corey EJ, Schreiber SL. A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci USA. 91:1994;3358-3362.
16. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13-21.
17. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. 78:1994;773-785.
18. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 349:1991;132-138.
19. Fenteany G, Schreiber SL. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem Biol. 3:1996;905-912.
20. Lum RT, Nelson MG, Joly A, Lee G, Meyer SM, Wick MM and Schow SR, Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamide. Bioorg Med Chem Lett, in press.
21. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase isolation and specificity of the bovine pituitary enzyme . J Neurochem. 35:1980;1172-1182.
22. Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry. 32:1993;1563-1572.
23. Lonergan SM, Johnson MN, Calkins CR. Improved calpain assay using fluorescein isothiocyanate-labeled casein. J Food Sci. 60:1995;72-78.
24. Dignam JD, Lebovitz RM, Roeder R. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1488.
25. Freudenberg MA, Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect Immunity. 59:1991;2110-2115.
26. Schow SR, Joly A. N-Acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-κB activation and prevents TNF and IL-6 synthesis in vivo. Cell Immunol. 175:1997;199-202.